FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 741 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... June 23, 2023 Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... September 1, 2020 First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... March 24, 2026 Sustainability a major focus of our 17th year partnering with TK... October 11, 2021 Load more HOT NEWS Woman Died From Stage IV Breast Cancer After Doctor Misread Her... Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected When Natural Disasters Strike, This Program Helps Provide Relief To People... Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of...
